Related Experiment Videos
Rationally designed anti-mitotic agents with pro-apoptotic activity.
1Drug Discovery Program, Parker Hughes Cancer Center, Parker Hughes Institute, 2665 Long Lake Road, St. Paul, Minnesota 55113, USA. Uckun@ih.org
Current Pharmaceutical Design
|September 20, 2001
Summary
New anticancer agents targeting tubulin, including SPIKET and COBRA compounds, show potent cytotoxicity and microtubule disruption. Phorboxazole analogs and BTK inhibitors also demonstrate significant anti-cancer and pro-apoptotic activity in various cancer cell lines.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Tubulin, a key cytoskeletal protein, is a validated target for anticancer drug development.
- Synthetic compounds like SPIKET and COBRA, along with natural products such as phorboxazoles, interact with tubulin at distinct binding sites.
- Inhibitors of Bruton's tyrosine kinase (BTK) also represent a promising class of anti-cancer agents.
Purpose of the Study:
- To investigate the anticancer potential of novel tubulin-targeting agents (SPIKET, COBRA compounds) and phorboxazole analogs.
- To evaluate the cytotoxic and apoptotic effects of these compounds on various cancer cell lines.
- To explore the structure-activity relationships of phorboxazole analogs and the role of BTK inhibition in cancer therapy.
Main Methods:
- Synthesis and characterization of SPIKET and COBRA compounds.
- In vitro assays to assess tubulin polymerization inhibition and cytotoxicity (MTT assays).
- Microtubule organization assessment and apoptosis induction studies in cancer cells.
- Structure-activity relationship analysis of phorboxazole analogs.
- Inhibition assays for BTK and evaluation of chemotherapy-induced apoptosis.
Main Results:
- SPIKET compound SPIKET-P induced tubulin depolymerization and potent cytotoxicity at nanomolar concentrations.
- COBRA-1 inhibited tubulin polymerization, disrupted microtubule organization, and induced apoptosis in breast cancer and brain tumor cells.
- Synthetic phorboxazole A and its analogs (2 and 3) exhibited potent cytotoxicity against leukemia, breast cancer, and glioblastoma cells.
- Anticancer activity of phorboxazoles correlated with specific structural moieties, suggesting bimodal interactions.
- Leflunomide metabolite analog LFM-A13 inhibited BTK and enhanced chemotherapy-induced apoptosis in leukemic cells.
Conclusions:
- Novel synthetic compounds targeting tubulin, such as SPIKET and COBRA, display significant anticancer activity.
- Phorboxazoles and their analogs are potent cytostatic and cytotoxic agents, with activity linked to specific structural features.
- BTK inhibition represents a viable strategy for enhancing cancer cell sensitivity to chemotherapy and inducing apoptosis.